Lanean...

Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution

Novel immune checkpoint blockade with ipilimumab, an antibody blocking the cytotoxic T-lymphocyte antigen 4 (CTLA4), is revolutionizing cancer therapy. However, ipilimumab induces symptomatic, sometimes severe, endocrine immune-related adverse events (irAEs) that are inconsistently recognized and re...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Endocr Relat Cancer
Egile Nagusiak: Ryder, Mabel, Callahan, Margaret, Postow, Michael A, Wolchok, Jedd, Fagin, James A
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2014
Gaiak:
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4573438/
https://ncbi.nlm.nih.gov/pubmed/24610577
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1530/ERC-13-0499
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!